IP Verse

Nant competitive analysis

Latest publications and patents of Nant New

Explore the latest publications and patents granted to Nant, showcasing their recent innovations and technological advancements.

Last updated on: Sep 23, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Nant

EP3059307
May 4, 2022Use Of A Laminin For Differentiating Pluripotent Cells Into Hepatocyte Lineage CellsPatent Maintained As Amended
EP3256573
Dec 9, 2020Recombinant Adeno-Associated Virus Particle Purification With Multiple-Step Anion Exchange ChromatographyGranted And Under Opposition
EP3256574
Nov 25, 2020Recombinant Adeno-Associated Virus Particle Purification Comprising An Affinity Purification StepGranted And Under Opposition
EP207306083
May 4, 2018Heating Incombustible Cigarette That Does Not Contain Material Of Being Fuming Props Up -
EP2285914
Jan 10, 2018Novel Environmental Friendly Anti-Microbial Adhesion Agents For Anti-Fouling Paints And Anti-Fouling Paints Containing ThemNo Opposition Filed Within Time Limit
EP2914253
Jan 3, 2018Cyclic Sulfonamide Containing Derivatives As Inhibitors Of Hedgehog Signaling PathwayNo Opposition Filed Within Time Limit
EP203723430
Jul 23, 2014Suction Pipe Composite Filter Stick And Suction Pipe Composite Filter Tip -
EP102342583
Apr 24, 2013Filter Stick Containing Tobacco Particles And Preparation Method Thereof -
EP202005243
Oct 12, 2011Ternary Composite Filter Tip -
EP4549647
Oct 29, 1985Apparatus For The Transfer Of Articles Between Two Machines -

Latest oppositions filed by Nant

Explore patent oppositions filed by Nant against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3570885
Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)AMGENJun 16, 2025
EP3684786
Mutated Glycoprotein Of Vesicular Stomatitis VirusCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSMay 14, 2025
EP3506931
Methods For Preventing Or Treating Allergy By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSApr 30, 2025
EP3889181
Methods For Treating Atopic Dermatitis By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJan 24, 2025
EP3820625
Device For Dispensing A Fluid Product, And Method For Filling And For Plugging SameAPTAR FRANCEDec 12, 2024
EP3818078
Methods Of Producing Recombinant ProteinsBRISTOL MYERS SQUIBBNov 26, 2024
EP3585402
Compositions, Articles Of Manufacture And Methods Related To Dosing In Cell TherapyJUNO THERAPEUTICSNov 12, 2024
EP3515465
Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALSNov 6, 2024
EP3973987
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSOct 10, 2024
EP3703818
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJul 30, 2024

Latest patents of Nant opposed by its competitors

Explore Nant's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3059307
May 4, 2022Use Of A Laminin For Differentiating Pluripotent Cells Into Hepatocyte Lineage Cells1
EP3256573
Dec 9, 2020Recombinant Adeno-Associated Virus Particle Purification With Multiple-Step Anion Exchange Chromatography1
EP3256574
Nov 25, 2020Recombinant Adeno-Associated Virus Particle Purification Comprising An Affinity Purification Step7

Latest PTAB cases involving Nant

Discover the latest PTAB cases involving Nant, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 29, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Nant

IPR2021-01387Aug 27, 2021BANK OF AMERICANANTTerminated-Settled
IPR2021-01388Aug 26, 2021BANK OF AMERICANANTInstitution Denied
IPR2021-01389Aug 22, 2021BANK OF AMERICANANTInstitution Denied
IPR2021-01332Aug 8, 2021BANK OF AMERICANANTFinal Written Decision
IPR2021-01333Aug 6, 2021BANK OF AMERICANANTFinal Written Decision
IPR2021-01304Jul 24, 2021BANK OF AMERICANANTFinal Written Decision
IPR2021-01081Jun 21, 2021BANK OF AMERICA NANANTFinal Written Decision
IPR2021-01080Jun 16, 2021BANK OF AMERICA NANANTTerminated-Settled
IPR2021-01133Jun 15, 2021NIANTICNANTInstitution Denied
IPR2021-01119Jun 14, 2021NIANTICNANTInstitution Denied

Peer Comparison New

IP litigation analysis comparing Nant with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
BOULT WADE TENNANT52 - - - Highly Aggressive
DANA FARBER CANCER INSTITUTE - 1431Defensive
REGENERON PHARMACEUTICALS3893930Balanced
SANOFI BIOTECHNOLOGY - 50 - - Non-Active